Pharmaceutical

The VPAS fallout continues – Celltrion pulls high-profile biosimilar from UK market

In late June 2023, Celltrion (South Korea) withdrew its key anti-cancer biosimilar, Herzuma, from the UK market.

Jul 3, 2023 - 20:00
The VPAS fallout continues – Celltrion pulls high-profile biosimilar from UK market
In late June 2023, Celltrion (South Korea) withdrew its key anti-cancer biosimilar, Herzuma, from the UK market.
Read the original article

Tags:

Previous Article

Zealand Pharma submits NDA for hyperinsulinism drug dasiglucagon

Next Article

Camena bags $10m in funding from Mercia

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Bristol-Myers Squibb sees highest patent filings and grants during August in Q3 2023

Bristol-Myers Squibb sees highest patent filings and gr...

Nov 24, 2023

As kids, they underwent a common test for UTIs. As adults, it haunts them as a traumatic ‘nightmare’

As kids, they underwent a common test for UTIs. As adul...

Sep 12, 2023

STAT+: EQRx, failed developer of low-priced cancer drugs, is sold for cash

STAT+: EQRx, failed developer of low-priced cancer drug...

Aug 1, 2023